세계 생물학적 안전성 시험용 제품 및 서비스 시장 : 규모, 제품별, 용도별, 시험별, 지역별 부문: 동향 분석 보고서(2024-2030년)

Biological Safety Testing Products And Services Market Growth & Trends:

The global biological safety testing products and services market size is expected to reach USD 9.30 billion by 2030, registering a CAGR of 10.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is predominantly driven by the increasing production of biologics, boosting the demand for highly effective biological safety testing tools. The increasing disease burden is expected to be a major factor responsible for the rising production of biologics, thereby propelling the market growth.

The increasing prevalence of chronic diseases associated with lifestyle, including diabetes and cancer, is a key factor contributing to the rise in drug development and subsequent commercialization. This is expected to increase the need for ensuring & scrutinizing the safety of specialized and targeted therapies, evaluating outcomes, and circumventing probable shortcomings. In addition, biotechnology and pharmaceutical companies are increasingly integrating biological safety testing products and services to produce contamination-free and highly potent biologics to cater to the large number of people suffering from target diseases. Safety testing for viral conditions is proving to be one of the primary concerns of most companies as it is a critical component of manufacturing, chemistry, and control of biologics. This is fueling growth opportunities in the market.

Laboratory-based contamination is leading to the development and refinement of workstations by incorporating biological safety products and services. The increasing need to work with tissue cultures, maintain the sterility of cell lines, and minimize cross-contamination has increased concerns regarding product integrity. Rising involvement by government healthcare organizations for implementing good manufacturing practices and subsequent testing & control at every production stage is expected to widen the scope for growth.

Furthermore, key players operating in the biological safety testing product & services market are constantly focusing on developing novel products and technologies, further expanding their product portfolio, and to meet the rising demand for biological safety testing globally. For instance, in December 2022, -Charles River Laboratories International, Inc. announced the launch of Endosafe Nexus 200, a fully robotic instrument capable of processing both complex or undiluted, serial dilutions for water, in-process, and final product testing, further expanding its endotoxin testing portfolio. The incorporation of automation through robotics has enabled streamlining the quality control process and subsequently improving overall process efficiency.

Biological Safety Testing Products And Services Market Report Highlights:

• Based on product, the reagents and kits segment held a leading revenue share of over 39.9% in 2023due to their extensive use in research and clinical laboratories
• Based on application, the vaccines & therapeutics segment dominated in terms of market share in 2023 and is anticipated to grow at fastest growth rate owing to the increase in disease outbreaks over the years
• Based on test type, the endotoxin tests segment dominated in terms of the market share of in 2023 owing to the rising prevalence of bacterial infections
• North America dominated the overall market with a revenue share of 35.13% in 2023, owing to rising research investments in biotechnology and the growing burden of chronic diseases. This anticipates increasing the demand for molecular cytogenetics in the region over the forecast period
• Asia Pacific is anticipated to grow at the fastest growth rate over the forecast period due to growing healthcare spending and the development of healthcare infrastructure in developing countries like India and China

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Application Segment
    • 1.1.1.3. Test Type Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Primary Sources
• 1.11. List of Abbreviations

Chapter 2. Biological Safety Testing Products & Services Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Products and Services Snapshots
• 2.3. Application And End-use Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Biological Safety Testing Products & Services Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Increase number of government initiatives and recommendations
  • 3.4.2. Increasing production of new biologics due to high disease burden
  • 3.4.3. High R&D investments in clinical research and life sciences research
• 3.5. Market Restraint Analysis
  • 3.5.1. Time-consuming approval process
• 3.6. Biological Safety Testing Products & Services Market Analysis Tools
  • 3.6.1. Industry Analysis - Porter's Five Forces
    • 3.6.1.1. Supplier Power
    • 3.6.1.2. Buyer Power
    • 3.6.1.3. Substitution Threat
    • 3.6.1.4. Threat of New Entrant
    • 3.6.1.5. Competitive Rivalry
  • 3.6.2. PESTLE Analysis
    • 3.6.2.1. Political Landscape
    • 3.6.2.2. Economic Landscape
    • 3.6.2.3. Social Landscape
    • 3.6.2.4. Technological Landscape
    • 3.6.2.5. Environmental Landscape
    • 3.6.2.6. Legal Landscape

Chapter 4. Biological Safety Testing Products & Services Market: Products Estimates & Trend Analysis

• 4.1. Product Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Biological Safety Testing Products & Services Market By Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 To 2030 For The Following
  • 4.4.1. Reagents & Kits
    • 4.4.1.1. Market Estimates and Forecasts 2018 To 2030, (USD Million)
  • 4.4.2. Services
    • 4.4.2.1. Market Estimates and Forecasts 2018 To 2030, (USD Million)
  • 4.4.3. Instruments
    • 4.4.3.1. Market Estimates and Forecasts 2018 To 2030, (USD Million)

Chapter 5. Biological Safety Testing Products & Services Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Biological Safety Testing Products & Services Market By Application Outlook
• 5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
  • 5.4.1. Vaccine & Therapeutics Market Revenue Estimates and Forecasts (USD Million, 2018 - 2030)
    • 5.4.1.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
    • 5.4.1.1.1. Vaccines Market Estimates And Forecasts (USD Million, 2018 - 2030)
    • 5.4.1.1.1.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
    • 5.4.1.1.2. Monoclonal Antibodies Market Estimates And Forecasts (USD Million, 2018 - 2030)
    • 5.4.1.1.2.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
    • 5.4.1.1.3. Recombinant Protein Market Estimates And Forecasts (USD Million, 2018 - 2030)
    • 5.4.1.1.3.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 5.4.2. Blood & Blood-based Products Market Revenue Estimates and Forecasts (USD Million, 2018 - 2030)
    • 5.4.2.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 5.4.3. Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 5.4.4. Tissue & Tissue-based Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 5.4.5. Stem Cells Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.5.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)

Chapter 6. Biological Safety Testing Products & Services Market: Test Type Estimates & Trend Analysis

• 6.1. Test Type Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Biological Safety Testing Products & Services Market By Test Type Outlook
• 6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
  • 6.4.1. Endotoxin Tests
    • 6.4.1.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 6.4.2. Sterility Tests
    • 6.4.2.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 6.4.3. Cell Line Authentication & Characterization Tests
    • 6.4.3.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 6.4.4. Bioburden Tests
    • 6.4.4.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 6.4.5. Adventitious Agent Detection Tests
    • 6.4.5.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 6.4.6. Residual Host Contamination Detection Tests
    • 6.4.6.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 6.4.7. Others
    • 6.4.7.1. Market Estimates And Forecasts (USD Million, 2018 - 2030)

Chapter 7. Regional Business Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key Country Dynamics
    • 7.5.1.2. Competitive Scenario
    • 7.5.1.3. Regulatory Framework
    • 7.5.1.4. U.S. Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.5.2. Canada
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Canada Market Estimates And Forecasts (USD Million, 2018 - 2030)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key Country Dynamics
    • 7.6.1.2. Competitive Scenario
    • 7.6.1.3. Regulatory Framework
    • 7.6.1.4. UK Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.6.2. Germany
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Germany Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.6.3. Spain
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Spain Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. France Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Italy Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.6.6. Denmark
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Denmark Market Estimates And Forecasts (USD Million, 2018 - 2030)
    • 7.6.6.5.
  • 7.6.7. Sweden
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Sweden Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.6.8. Norway
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Norway Market Estimates And Forecasts (USD Million, 2018 - 2030)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key Country Dynamics
    • 7.7.1.2. Competitive Scenario
    • 7.7.1.3. Regulatory Framework
    • 7.7.1.4. Japan Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.7.2. China
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. China Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.7.3. India
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. India Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.7.4. South Korea
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. South Korea Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.7.5. Thailand
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Thailand Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.7.6. Australia
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Australia Market Estimates And Forecasts (USD Million, 2018 - 2030)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key Country Dynamics
    • 7.8.1.2. Competitive Scenario
    • 7.8.1.3. Regulatory Framework
    • 7.8.1.4. Brazil Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.8.2. Mexico
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Mexico Biological Safety Testing Products & Services Market, 2018 - 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Argentina Market Estimates And Forecasts (USD Million, 2018 - 2030)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key Country Dynamics
    • 7.9.1.2. Competitive Scenario
    • 7.9.1.3. Regulatory Framework
    • 7.9.1.4. South Africa Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Saudi Arabia Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.9.3. UAE
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. UAE Market Estimates And Forecasts (USD Million, 2018 - 2030)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Competitive Scenario
    • 7.9.4.3. Regulatory Framework
    • 7.9.4.4. Kuwait Market Estimates And Forecasts (USD Million, 2018 - 2030)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company /Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of Key Distributors And Channel Partners
  • 8.3.2. Key Customers
  • 8.3.3. Key Company Market Share Analysis, 2023
  • 8.3.4. Charles River Laboratories
    • 8.3.4.1. Overview
    • 8.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.4.3. Product Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. BSL Bioservice
    • 8.3.5.1. Overview
    • 8.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.5.3. Product Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Merck KGaA
    • 8.3.6.1. Overview
    • 8.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.6.3. Product Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Samsung Biologics
    • 8.3.7.1. Overview
    • 8.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.7.3. Product Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Sartorius AG
    • 8.3.8.1. Overview
    • 8.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.8.3. Product Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Eurofins Scientific
    • 8.3.9.1. Overview
    • 8.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.9.3. Product Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. SGS Societe Generale de Surveillance SA
    • 8.3.10.1. Overview
    • 8.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.10.3. Product Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Thermo Fisher Scientific Inc.
    • 8.3.11.1. Overview
    • 8.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.11.3. Product Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. BIOMERIEUX
    • 8.3.12.1. Overview
    • 8.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.12.3. Product Benchmarking
    • 8.3.12.4. Strategic Initiatives
  • 8.3.13. Lonza
    • 8.3.13.1. Overview
    • 8.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.13.3. Product Benchmarking
    • 8.3.13.4. Strategic Initiatives